Societal CDMO, Inc.

$1.10+0.92%(+$0.01)
TickerSpark Score
67/100
Solid
65
Valuation
45
Profitability
70
Growth
56
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCTL research report →

52-Week Range82% of range
Low $0.26
Current $1.10
High $1.28

Companywww.societalcdmo.com

Societal CDMO, Inc. , a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

CEO
J. David Enloe Jr.
IPO
2014
Employees
258
HQ
Exton, PA, US

Price Chart

+2.80% · this period
$1.12$0.71$0.30Apr 06Oct 06Apr 08

Valuation

Market Cap
$116.13M
P/E
-7.89
P/S
1.23
P/B
1.79
EV/EBITDA
26.49
Div Yield
0.00%

Profitability

Gross Margin
19.54%
Op Margin
-1.86%
Net Margin
-14.03%
ROE
-22.40%
ROIC
-1.24%

Growth & Income

Revenue
$94.64M · 4.90%
Net Income
$-13,274,000 · 33.23%
EPS
$-0.14 · 58.82%
Op Income
$-1,759,000
FCF YoY
3.50%

Performance & Tape

52W High
$1.28
52W Low
$0.26
50D MA
$0.78
200D MA
$0.61
Beta
1.58
Avg Volume
998.39K

Get TickerSpark's AI analysis on SCTL

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 8, 24Arens Mathew Paulsell1,250,000
Apr 8, 24Arens Mathew Paulsell20,000
Apr 8, 24Arens Mathew Paulother19,676,396
Apr 8, 24Weisman Wayneother234,982
Apr 8, 24Weisman Waynesell73,620
Apr 8, 24Weisman Waynesell118,182
Apr 8, 24Weisman Waynesell27,229
Apr 8, 24Reasons Bryan M.other217,429
Apr 8, 24Reasons Bryan M.sell118,182
Apr 8, 24Reasons Bryan M.sell27,229

Our SCTL Coverage

We haven't published any research on SCTL yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate SCTL Report →

Similar Companies